Therapy Area
Novocure’s TTFields device slows metastasis in NSCLC
Novocure’s tumour treating fields therapy met the primary endpoint in Phase III trials and slowed the progression of brain metastasis of NSCLC.
Novocure’s tumour treating fields therapy met the primary endpoint in Phase III trials and slowed the progression of brain metastasis of NSCLC.